tiprankstipranks
Trending News
More News >
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Advertisement

Revance Therapeutics (RVNC) Stock Statistics & Valuation Metrics

Compare
626 Followers

Total Valuation

Revance Therapeutics has a market cap or net worth of $381.02M. The enterprise value is ―.
Market Cap$381.02M
Enterprise Value

Share Statistics

Revance Therapeutics has 104,389,885 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding104,389,885
Owned by Insiders2.01%
Owned by Institutions0.46%

Financial Efficiency

Revance Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee392.03K
Profits Per Employee-542.69K
Employee Count597
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio1.55
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, Revance Therapeutics had revenue of 234.04M and earned -323.99M in profits. Earnings per share was -3.83.
Revenue234.04M
Gross Profit81.88M
Operating Income-316.78M
Pretax Income-323.69M
Net Income-323.99M
EBITDA-290.64M
Earnings Per Share (EPS)-3.83

Cash Flow

In the last 12 months, operating cash flow was -190.89M and capital expenditures -4.02M, giving a free cash flow of -194.91M billion.
Operating Cash Flow-190.89M
Free Cash Flow-194.91M
Free Cash Flow per Share-1.87

Dividends & Yields

Revance Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.46
52-Week Price Change-8.98%
50-Day Moving Average
200-Day Moving Average
Relative Strength Index (RSI)
Average Volume (3m)

Important Dates

Revance Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date
Next Earnings Date
Ex-Dividend Date

Financial Position

Revance Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, Revance Therapeutics has paid 300.00K in taxes.
Income Tax300.00K
Effective Tax Rate

Enterprise Valuation

Revance Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

Revance Therapeutics has $184.08M in cash and marketable securities with $483.45M in debt, giving a net cash position of $299.37M billion.
Cash & Marketable Securities$184.08M
Total Debt$483.45M
Net Cash$299.37M
Net Cash Per Share$2.87
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for Revance Therapeutics is $3.05, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$3.05
Price Target Upside-16.44% Downside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast15.33%
EPS Growth Forecast61.49%

Scores

Smart Score2
AI Score41
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis